Clinical trial with subdermal implants containing norgestrienone

S. Diaz, M. Pavez, E. Quinteros, J. Diaz, D. N. Robertson, H. B. Croxatto

Resultado de la investigación: Article

2 Citas (Scopus)

Resumen

Norgestrienone implants delivering approximately 225 μg/day were tested clinically for contraceptive effectiveness and acceptability in 145 women. Five pregnancies occurred in 2259 woman-months of use, one in the 11th month, one in the 15th and three in the 16th month of use. Continuation rate at 12 months was 86.7. The number of bleeding runs and bleeding days was increased in approximately 12% of the subjects. Ten percent of the patients had no bleeding in the first 90 days of treatment. Changes in bleeding pattern led to closures in four cases. Headache and signs of mild androgenicity were among the leading side effects. Blood and urine analysis throughout the study showed normal values of 17 different parameters, but a tendency to lower cholesterolemia not associated with changes in thyroid hormone levels, was observed in several patients. Cortisol was found slightly under the lower normal range in one subject without clinical manifestations of hypoadrenalism. It is concluded that norgestrienone implants should be replaced every twelve months for maximal contraceptive effect and because of their efficacy and good acceptability, evaluation of their long term use is warranted.

Idioma originalEnglish
Páginas (desde-hasta)429-440
Número de páginas12
PublicaciónContraception
Volumen18
N.º4
DOI
EstadoPublished - 1 ene 1978

Huella dactilar

Norgestrienone
Clinical Trials
Hemorrhage
Contraceptive Agents
Reference Values
Adrenal Insufficiency
Thyroid Hormones
Headache
Hydrocortisone
Urine
Pregnancy

ASJC Scopus subject areas

  • Reproductive Medicine
  • Obstetrics and Gynaecology

Citar esto

Diaz, S. ; Pavez, M. ; Quinteros, E. ; Diaz, J. ; Robertson, D. N. ; Croxatto, H. B. / Clinical trial with subdermal implants containing norgestrienone. En: Contraception. 1978 ; Vol. 18, N.º 4. pp. 429-440.
@article{f897ca0225884082a0c8326d9ed12ee1,
title = "Clinical trial with subdermal implants containing norgestrienone",
abstract = "Norgestrienone implants delivering approximately 225 μg/day were tested clinically for contraceptive effectiveness and acceptability in 145 women. Five pregnancies occurred in 2259 woman-months of use, one in the 11th month, one in the 15th and three in the 16th month of use. Continuation rate at 12 months was 86.7. The number of bleeding runs and bleeding days was increased in approximately 12{\%} of the subjects. Ten percent of the patients had no bleeding in the first 90 days of treatment. Changes in bleeding pattern led to closures in four cases. Headache and signs of mild androgenicity were among the leading side effects. Blood and urine analysis throughout the study showed normal values of 17 different parameters, but a tendency to lower cholesterolemia not associated with changes in thyroid hormone levels, was observed in several patients. Cortisol was found slightly under the lower normal range in one subject without clinical manifestations of hypoadrenalism. It is concluded that norgestrienone implants should be replaced every twelve months for maximal contraceptive effect and because of their efficacy and good acceptability, evaluation of their long term use is warranted.",
author = "S. Diaz and M. Pavez and E. Quinteros and J. Diaz and Robertson, {D. N.} and Croxatto, {H. B.}",
year = "1978",
month = "1",
day = "1",
doi = "10.1016/0010-7824(78)90027-6",
language = "English",
volume = "18",
pages = "429--440",
journal = "Contraception",
issn = "0010-7824",
publisher = "Elsevier USA",
number = "4",

}

Diaz, S, Pavez, M, Quinteros, E, Diaz, J, Robertson, DN & Croxatto, HB 1978, 'Clinical trial with subdermal implants containing norgestrienone', Contraception, vol. 18, n.º 4, pp. 429-440. https://doi.org/10.1016/0010-7824(78)90027-6

Clinical trial with subdermal implants containing norgestrienone. / Diaz, S.; Pavez, M.; Quinteros, E.; Diaz, J.; Robertson, D. N.; Croxatto, H. B.

En: Contraception, Vol. 18, N.º 4, 01.01.1978, p. 429-440.

Resultado de la investigación: Article

TY - JOUR

T1 - Clinical trial with subdermal implants containing norgestrienone

AU - Diaz, S.

AU - Pavez, M.

AU - Quinteros, E.

AU - Diaz, J.

AU - Robertson, D. N.

AU - Croxatto, H. B.

PY - 1978/1/1

Y1 - 1978/1/1

N2 - Norgestrienone implants delivering approximately 225 μg/day were tested clinically for contraceptive effectiveness and acceptability in 145 women. Five pregnancies occurred in 2259 woman-months of use, one in the 11th month, one in the 15th and three in the 16th month of use. Continuation rate at 12 months was 86.7. The number of bleeding runs and bleeding days was increased in approximately 12% of the subjects. Ten percent of the patients had no bleeding in the first 90 days of treatment. Changes in bleeding pattern led to closures in four cases. Headache and signs of mild androgenicity were among the leading side effects. Blood and urine analysis throughout the study showed normal values of 17 different parameters, but a tendency to lower cholesterolemia not associated with changes in thyroid hormone levels, was observed in several patients. Cortisol was found slightly under the lower normal range in one subject without clinical manifestations of hypoadrenalism. It is concluded that norgestrienone implants should be replaced every twelve months for maximal contraceptive effect and because of their efficacy and good acceptability, evaluation of their long term use is warranted.

AB - Norgestrienone implants delivering approximately 225 μg/day were tested clinically for contraceptive effectiveness and acceptability in 145 women. Five pregnancies occurred in 2259 woman-months of use, one in the 11th month, one in the 15th and three in the 16th month of use. Continuation rate at 12 months was 86.7. The number of bleeding runs and bleeding days was increased in approximately 12% of the subjects. Ten percent of the patients had no bleeding in the first 90 days of treatment. Changes in bleeding pattern led to closures in four cases. Headache and signs of mild androgenicity were among the leading side effects. Blood and urine analysis throughout the study showed normal values of 17 different parameters, but a tendency to lower cholesterolemia not associated with changes in thyroid hormone levels, was observed in several patients. Cortisol was found slightly under the lower normal range in one subject without clinical manifestations of hypoadrenalism. It is concluded that norgestrienone implants should be replaced every twelve months for maximal contraceptive effect and because of their efficacy and good acceptability, evaluation of their long term use is warranted.

UR - http://www.scopus.com/inward/record.url?scp=0018137583&partnerID=8YFLogxK

U2 - 10.1016/0010-7824(78)90027-6

DO - 10.1016/0010-7824(78)90027-6

M3 - Article

AN - SCOPUS:0018137583

VL - 18

SP - 429

EP - 440

JO - Contraception

JF - Contraception

SN - 0010-7824

IS - 4

ER -